Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 18/20 | 1.00 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15544111 | 1.00 | AR (1.00) | ARIDO1CYP3A4 | |
| SCHEMBL15543538 | 0.89 | AR (1.00) | ARIDO1CYP3A4 | |
| SCHEMBL15543537 | 0.89 | AR (1.00) | ARIDO1CYP3A4 | |
| SCHEMBL15543829 | 0.86 | AR (1.00) | AR | |
| SCHEMBL15543831 | 0.86 | AR (1.00) | AR | |
| SCHEMBL15543256 | 0.83 | AR (1.00) | ARIDO1CYP3A4 | |
| SCHEMBL15543253 | 0.83 | AR (1.00) | ARIDO1CYP3A4 | |
| SCHEMBL15543431 | 0.78 | AR (1.00) | ARIDO1 | |
| SCHEMBL15543428 | 0.78 | AR (1.00) | ARIDO1 | |
| SCHEMBL15543226 | 0.78 | AR (1.00) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864291-B1 | N-[4-(QUINOLIN-4-YLOXY)CYCLOHEXYL(METHYL)](HETERO)ARYLCARBOXAMIDES AS ANDROGEN RECEPTOR ANTAGONISTS, PRODUCTION AND USE THEREOF AS MEDICINAL PRODUCTS | Bayer Pharma AG (DE) | 2016-10-05 | — | — | EP | claimed |
| US-9428460-B2 | N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-30 | — | — | US | claimed |
| US-20150191431-A1 | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-09 | — | — | US | claimed |
| EP-2864291-A1 | N-[4-(QUINOLIN-4-YLOXY)CYCLOHEXYL(METHYL)](HETERO)ARYLCARBOXAMIDES AS ANDROGEN RECEPTOR ANTAGONISTS, PRODUCTION AND USE THEREOF AS MEDICINAL PRODUCTS | Bayer Pharma Aktiengesellschaft (DE) | 2015-04-29 | — | — | EP | claimed |
| WO-2014001247-A1 | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-03 | — | — | WO | claimed |
| EP-2864291-B1 | N-[4-(QUINOLIN-4-YLOXY)CYCLOHEXYL(METHYL)](HETERO)ARYLCARBOXAMIDES AS ANDROGEN RECEPTOR ANTAGONISTS, PRODUCTION AND USE THEREOF AS MEDICINAL PRODUCTS | Bayer Pharma AG (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-9428460-B2 | N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-30 | — | — | US | disclosed |
| US-9428460-B2 | N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-30 | — | — | US | disclosed |
| US-9428460-B2 | N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-30 | — | — | US | disclosed |
| US-20150191431-A1 | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-09 | — | — | US | disclosed |
| US-20150191431-A1 | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-09 | — | — | US | disclosed |
| US-20150191431-A1 | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-09 | — | — | US | disclosed |
| EP-2864291-A1 | N-[4-(QUINOLIN-4-YLOXY)CYCLOHEXYL(METHYL)](HETERO)ARYLCARBOXAMIDES AS ANDROGEN RECEPTOR ANTAGONISTS, PRODUCTION AND USE THEREOF AS MEDICINAL PRODUCTS | Bayer Pharma Aktiengesellschaft (DE) | 2015-04-29 | — | — | EP | disclosed |
| WO-2014001247-A1 | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191431-A1 | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | AR, NR5A1, CYP19A1 | AR 1/4885IDO1 987/4885CYP3A4 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.